Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.

Published

Journal Article

We determined the timing of ischemic complications within 30 days after percutaneous coronary intervention (PCI) in patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Complications (death, myocardial infarction [MI], target vessel revascularization) occurred in 178 of 2064 patients (8.6%) within 30 days. More than 85% of complications occurred within the 24 hours following randomization, with the greatest risk hazard at 12-18 hours. Unexpectedly, 31% of patients who ultimately met criteria for an endpoint MI within 24 hours of PCI had completely normal CK-MB concentrations at the first 6-hour measurement. There was no rebound increase in events after cessation of eptifibatide. Treatment benefit persisted to 30 days. Post-procedural MI is often not detected until greater than or equal to 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications.

Full Text

Duke Authors

Cited Authors

  • Cantor, WJ; Tcheng, JE; Blankenship, JC; O'Shea, JC; Pieper, KS; Criger, DA; Madan, M; Ducas, J; Sheldon, WS; Tannenbaum, MA; Smith, JE; Kitt, MM; Gilchrist, IC

Published Date

  • September 2004

Published In

Volume / Issue

  • 16 / 9

Start / End Page

  • 475 - 481

PubMed ID

  • 15353828

Pubmed Central ID

  • 15353828

Electronic International Standard Serial Number (EISSN)

  • 1557-2501

International Standard Serial Number (ISSN)

  • 1042-3931

Language

  • eng